Darexaban vs placebo for prevention of VTE in Asian patients receiving TKA or THA
Darexaban for the Prevention of Venous Thromboembolism in Asian Patients Undergoing Orthopedic Surgery: Results From 2 Randomized, Placebo-Controlled, Double-Blind StudiesClin Appl Thromb Hemost. 2014 Mar;20(2):199-211
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
996 Asian patients undergoing TKA (1 study) and THA (second study) surgery were randomly assigned into 1 of 4 groups to determine if darexaban effectively and safely reduced the occurrence of venous thromboembolism (VTE) when compared to an oral placebo or subcutaneous enoxaparin. The four possible treatment methods were: a 15 or 30 mg oral dose of darexaban, a 20 mg subcutaneous injection of enox...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue